tiprankstipranks
Advertisement
Advertisement

ACRV Stock Latest News

Acrivon Therapeutics: Buy Rating Reaffirmed as Pipeline Progress Supports Attractive Valuation; $19 Price Target Maintained
RatingsAcrivon Therapeutics: Buy Rating Reaffirmed as Pipeline Progress Supports Attractive Valuation; $19 Price Target Maintained
3d ago
ACRV
Acrivon Therapeutics: Buy Rating Reiterated as ACR-2316’s Emerging Clinical Profile and Differentiated Safety Support Unchanged $19 Price Target
PremiumRatings
Acrivon Therapeutics: Buy Rating Reiterated as ACR-2316’s Emerging Clinical Profile and Differentiated Safety Support Unchanged $19 Price Target
10d ago
ACRV
Acrivon Shareholders Approve Expanded Equity Plan and Directors
PremiumCompany Announcements
Acrivon Shareholders Approve Expanded Equity Plan and Directors
2M ago
8K
ACRV
Acrivon Therapeutics assumed with an Outperform at Oppenheimer
PremiumThe Fly
Acrivon Therapeutics assumed with an Outperform at Oppenheimer
2M ago
ACRV
Acrivon Pharmaceuticals: Buy Rating Backed by Strong Cash Runway and Promising ACR-368 Phase 2 Efficacy
PremiumRatings
Acrivon Pharmaceuticals: Buy Rating Backed by Strong Cash Runway and Promising ACR-368 Phase 2 Efficacy
3M ago
ACRV
Acrivon Biosciences: Advancing ACR‑368 and ACR‑2316 Pipeline Underpins Buy Rating and Long Cash Runway
PremiumRatingsAcrivon Biosciences: Advancing ACR‑368 and ACR‑2316 Pipeline Underpins Buy Rating and Long Cash Runway
3M ago
ACRV
Analyst Reiterates Buy on Acrivon, Maintains $19 Price Target Amid Progress of ACR-368 Trials
Premium
Ratings
Analyst Reiterates Buy on Acrivon, Maintains $19 Price Target Amid Progress of ACR-368 Trials
3M ago
ACRV
Acrivon Therapeutics reports Q1 EPS (49c), consensus (52c)
Premium
The Fly
Acrivon Therapeutics reports Q1 EPS (49c), consensus (52c)
3M ago
ACRV
Acrivon Highlights Positive ACR-368 Data and 2025 Results
PremiumCompany Announcements
Acrivon Highlights Positive ACR-368 Data and 2025 Results
5M ago
8K
ACRV
Acrivon plans to initiate fourth cohort in ACR-368 Phase 2b study
PremiumThe Fly
Acrivon plans to initiate fourth cohort in ACR-368 Phase 2b study
5M ago
ACRV
Acrivon Therapeutics reports Q4 EPS (49c), consensus (46c)
PremiumThe Fly
Acrivon Therapeutics reports Q4 EPS (49c), consensus (46c)
5M ago
ACRV
Acrivon Therapeutics sees cash runway into 2Q27
PremiumThe Fly
Acrivon Therapeutics sees cash runway into 2Q27
5M ago
ACRV
ACR-368 in Serous Endometrial Cancer: Strong Phase 2b Efficacy, Manageable Safety, and a Clear Accelerated Approval Path Support Buy Rating on Acrivon
PremiumRatingsACR-368 in Serous Endometrial Cancer: Strong Phase 2b Efficacy, Manageable Safety, and a Clear Accelerated Approval Path Support Buy Rating on Acrivon
6M ago
ACRV
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data
Premium
Company Announcements
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data
6M ago
8K
ACRV
Acrivon Therapeutics announces completion, certification of CLIA certified lab
Premium
The Fly
Acrivon Therapeutics announces completion, certification of CLIA certified lab
6M ago
ACRV
3 Best Stocks to Buy Today, 1/22/2026, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Today, 1/22/2026, According to Top Analysts
7M ago
ACRV
META
Acrivon Therapeutics price target raised to $8 from $6 at Piper Sandler
PremiumThe Fly
Acrivon Therapeutics price target raised to $8 from $6 at Piper Sandler
7M ago
ACRV
Balancing Early Promise and Significant Uncertainty: Maintaining a Hold on Acrivon Therapeutics Amid Limited Data and Long-Dated Clinical Risk
PremiumRatings
Balancing Early Promise and Significant Uncertainty: Maintaining a Hold on Acrivon Therapeutics Amid Limited Data and Long-Dated Clinical Risk
7M ago
ACRV
Focused Clinical Strategy and Accelerated Approval Path for ACR-368 in High-Need Serous Endometrial Cancer Underpin ACRV Buy Rating
PremiumRatings
Focused Clinical Strategy and Accelerated Approval Path for ACR-368 in High-Need Serous Endometrial Cancer Underpin ACRV Buy Rating
7M ago
ACRV
Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
PremiumMarket NewsMorning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
7M ago
F
AEP
Acrivon Showcases Promising Phase 2b Oncology Data Update
Premium
Company Announcements
Acrivon Showcases Promising Phase 2b Oncology Data Update
7M ago
8K
ACRV
Acrivon Therapeutics Stock (ACRV) Sinks despite Positive Cancer Trial Results
Premium
Market News
Acrivon Therapeutics Stock (ACRV) Sinks despite Positive Cancer Trial Results
7M ago
ACRV

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >